1. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir;Cottrell;Clin. Pharmacokinet.,2013
2. Updated Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post-exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV: Interim Guidelines. Supplement to the 2016 Consolidated Guidelines on the Use of Antiretrovir;World Health Organization,2018
3. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients;Zhang;Br. J. Clin. Pharmacol.,2015
4. Update on the Transition to Dolutegravir-Based Antiretroviral Therapy: Report of a WHO Meeting, 29–30 March 2022;World Health Organization,2022
5. Neuropsychiatric adverse effects of dolutegravir in real-life clinical practice;Povar-Echeverría;Enferm. Infecc. Microbiol. Clín.,2021